A paid advertorial distributed through Newswire promotes NEOLISE Longevity, a subscription telehealth protocol built around CJC-1295 and ipamorelin, and discloses in its second paragraph that it is promotional and that a commission is earned on purchases. Credit where it is due: the disclosure is at the top, not buried in a footer.

CJC-1295 and ipamorelin are growth hormone secretagogues, compounds positioned as supporting the body's own growth hormone output rather than replacing it with synthetic HGH. The piece states plainly that neither compound is FDA-approved individually or as the marketed combination, and that compounded medications generally are not FDA-approved finished products.

The regulatory record

This is the part most peptide marketing leaves out, and the advertorial does not. FDA has identified potential significant safety risks associated with CJC-1295 in compounding contexts, citing immunogenicity, peptide-related impurities, limited clinical safety data, and reported adverse events including increased heart rate and systemic vasodilatory reaction.

FDA's Pharmacy Compounding Advisory Committee voted against including CJC-1295-related and ipamorelin-related bulk substances on the Section 503A Bulks List. For ipamorelin acetate, the concerns cited include a published report of serious adverse events, including death, when the compound was administered intravenously in a different clinical context.

What Section 503A actually is

Section 503A of the Federal Food, Drug, and Cosmetic Act sets conditions under which certain patient-specific compounded drugs may qualify for exemptions from standard approval requirements. It is not an approval, certification, or endorsement, a distinction the advertorial makes explicitly and one that a lot of compounded-peptide marketing blurs.

Who is filling the prescription

Plans run $239 to $299 a month depending on term length, with vials shipped cold-packed in batches of up to three months. The advertorial notes that NEOLISE's own site does not name the prescribing provider group or the compounding pharmacy by legal entity, and says comparable telehealth peptide and GLP-1 programs typically do.

Bottom line

An advertorial that names the FDA advisory committee vote against its own product's two active ingredients is an unusual document, and the unresolved item it flags is the specific chemical form of CJC-1295 being dispensed, which the materials reviewed did not specify. Published research on one form of the compound does not describe another, and that gap sits underneath everything else here.